Erectile Dysfunction
Common, treatable — and often the first sign of a vascular problem you cannot yet feel
What it is
Erectile dysfunction is the consistent or recurrent inability to get or keep an erection firm enough for satisfying sex. Occasional difficulty is near-universal and not a diagnosis; ED is the pattern that persists. It is very common — in the Massachusetts Male Aging Study, 52% of men aged 40 to 70 reported some degree of it, rising from about 39% at 40 to 67% at 70 — and it is one of the more treatable problems in medicine. It is also, importantly, not the same thing as low sexual desire: ED is a problem of the machinery of erection (largely blood flow and nerves), while low libido is a problem of drive. The two have different causes and different work-ups, and a drug that fixes one does nothing for the other.
Why it matters
For most men the erection is a blood-flow event, and the arteries that fill the penis are narrow — roughly 1 to 2 mm across — while the coronary arteries feeding the heart are two to three times wider. The same process, atherosclerosis and the endothelial dysfunction that precedes it, silts up the small vessels first, so it can show as erectile difficulty years before it shows as chest pain. This is not a metaphor: pooled cohort data find that men with ED carry roughly a 40-50% higher risk of future cardiovascular events and a modestly higher risk of dying from any cause, and in men who go on to develop symptomatic coronary disease, ED preceded the cardiac symptoms in about two of three cases, by an average of two to three years. That is why new erectile dysfunction — particularly in a man under about 60, or one with diabetes — is worth treating as a reason to check blood pressure, glucose and cholesterol, not only as a bedroom problem. The flip side is the good news: it usually responds to treatment, and the same steps that help the arteries help the erections.
What BioSignal knows about treating this
What works for Erectile Dysfunction
BioSignal’s clinical summary, most important first.
- PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) — effective first-line oral therapy for most causes
- Lifestyle and cardiovascular risk-factor reduction — weight loss, exercise, and stopping smoking measurably improve erectile function
- Treating the underlying driver — better glucose and blood-pressure control, and reviewing any medication that may contribute
- Testosterone therapy — but only where hypogonadism is confirmed on testing, not as a general ED treatment
- Addressing psychological contributors, including performance anxiety and relationship factors, sometimes with a therapist
- Second-line options where tablets fail: vacuum erection devices and intracavernosal (self-injected) therapy
- Penile prosthesis implantation as a durable last-line option
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
- Testosterone TherapyModerate confidence
Effective for genuine hypogonadism; no established benefit at normal levels. Suppresses fertility. Ask why testosterone is low before treating the number.
- Blood Pressure MedicationHigh confidence
Among the highest-value medicines ever made. The evidence isn't the problem — about half of people stop taking them, and that's where the strokes are.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Increasing age (the single strongest correlate, though ED is never simply 'normal ageing')
- Diabetes — ED affects roughly two-thirds of men with type 2 diabetes
- Cardiovascular disease and its risk factors: high blood pressure, high cholesterol, atherosclerosis
- Smoking (current smokers carry about a 50% higher risk)
- Obesity and a sedentary lifestyle
- Some medications — several antidepressants (SSRIs), and some older blood-pressure drugs
- Low testosterone / hypogonadism (more often affecting desire, but it can contribute)
- Psychological factors: performance anxiety, stress, depression, relationship difficulties
- Pelvic or prostate surgery, radiotherapy, and neurological conditions
- Excess alcohol
How it's diagnosed
The diagnosis is clinical — a careful history usually distinguishes the likely cause without special tests. A few features do a lot of work: erectile difficulty that came on gradually, is present in all situations, and comes with loss of morning and spontaneous erections points toward an organic (usually vascular) cause; difficulty that began suddenly, varies by situation, or spares morning erections points toward a psychological one. Because ED is a vascular marker, first-line assessment includes measuring blood pressure, fasting glucose or HbA1c, and a lipid profile, and estimating overall cardiovascular risk. A morning total testosterone is recommended, most usefully when desire is also reduced. Specialist tests (penile Doppler ultrasound, nocturnal tumescence studies) are reserved for selected cases — younger men, a history of pelvic trauma, or when surgery is being considered.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Related body systems
Frequently asked questions
Is erectile dysfunction a warning sign for heart problems?
It can be, and this is the most useful thing on this page. The arteries that fill the penis are much narrower than the arteries that feed the heart, so the early narrowing of atherosclerosis tends to cause trouble there first. Pooled studies of tens of thousands of men find that ED is associated with roughly a 40 to 50% higher risk of future cardiovascular events, and in men who later developed symptomatic coronary disease, the ED came first in about two-thirds of cases — on average two to three years earlier. This does not mean every man with ED has heart disease, and most cases are very treatable. But it does mean new ED, especially before about age 60 or with diabetes, is a good reason to have blood pressure, blood sugar and cholesterol checked. The erection is, in effect, an early stress test you did not sign up for.
Does low testosterone cause erectile dysfunction?
Usually it is not the main cause. Testosterone drives sexual desire more than the erection itself, so the pattern that points to a hormonal problem is ED together with clearly reduced libido, low energy and low mood — not ED with intact desire. That is why guidelines suggest checking a morning testosterone, most informatively when desire is also down. Where testosterone is genuinely low, treating it can help erections and can improve the response to ED tablets — but the benefit is concentrated in men with low levels; in men whose testosterone is normal, adding testosterone does not meaningfully improve erections and is not an appropriate treatment. Testosterone is a hormone to measure and correct if deficient, not a default remedy for ED.
Do Viagra and Cialis work — and are they safe?
They work well: the PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis, vardenafil, avanafil) are effective first-line treatment for most men, and large comparisons show them clearly better than placebo, with broadly similar safety. There is one safety point that genuinely matters: they must never be combined with nitrate heart medicines (nitroglycerin/GTN sprays and tablets, isosorbide) or with the pulmonary-hypertension drug riociguat, because together they can cause a sudden, dangerous fall in blood pressure. Men taking alpha-blockers or several blood-pressure medicines also need care with dosing. This is a conversation to have with a doctor or pharmacist rather than a purchase to make online — which matters all the more given the next question.
Do over-the-counter 'male enhancement' pills and testosterone boosters work?
Mostly no, and some are actively dangerous. An analysis of products the FDA flagged for hidden pharmaceutical ingredients found that sexual-enhancement supplements were the single largest category — 353 of 776 products — and nearly half of those contained undeclared sildenafil (the active drug in Viagra) or an unapproved chemical cousin of it. That is a real hazard: a man who avoids prescription ED tablets because he takes nitrates for his heart, and instead buys a 'natural' pill secretly spiked with the same class of drug, is taking exactly the combination that can be fatal. Separately, 'testosterone booster' supplements largely do not do what they claim — a review of 50 such products found published evidence of a testosterone increase for only about a quarter of the ingredients, and evidence of a decrease for some. The honest summary is that the effective treatments are the prescribed ones, and the shelf of pills promising otherwise is where the least trustworthy end of this market lives.
What is the difference between erectile dysfunction and low libido?
They are different problems and are often confused. Erectile dysfunction is a mechanical and vascular failure — the desire is there but the erection is not, or does not last. Low libido is a loss of the desire itself. They can occur together, but they point to different causes: ED leans toward blood vessels, nerves and medication effects, while low libido leans toward hormones, mood, medications and relationship factors. It matters because the treatments do not overlap — an ED tablet does nothing for absent desire, and treating desire does nothing for a plumbing problem. Getting the distinction right is the first step to getting the work-up right, which is why BioSignal keeps them separate.
Can lifestyle changes actually improve erections, or do I just need a pill?
They can, and the effect is real if modest. In a meta-analysis of randomised trials, lifestyle change and cardiovascular risk-factor reduction improved erectile-function scores by a small but genuine amount, on top of whatever medication achieved. The interventions with evidence are the unglamorous ones: regular physical activity, weight loss, stopping smoking, and controlling blood pressure, glucose and cholesterol. Because ED and vascular disease share a cause, these are not an alternative to treatment so much as treatment of the root — and they are the part that also lowers the heart risk the ED may be signalling. A tablet treats tonight; the lifestyle work treats the underlying artery.
Evidence summary
Erectile dysfunction is common, usually organic and vascular in older men, and generally very treatable. Its most under-communicated feature is prognostic: across pooled cohort studies, ED is associated with roughly a 40 to 50% increase in future cardiovascular events and a smaller increase in all-cause mortality, and it frequently precedes symptomatic coronary disease by two to three years — which makes new ED a legitimate prompt for cardiovascular risk assessment rather than only a sexual complaint. PDE5 inhibitors are effective first-line therapy for most men, with an absolute contraindication against combining them with nitrates or riociguat because of the risk of severe hypotension. Testosterone therapy improves erectile function mainly in men with confirmed hypogonadism and adds little when testosterone is normal; it is a deficiency treatment, not a general ED remedy, and desire rather than the erection is the better clue to a hormonal cause. Lifestyle and cardiovascular risk-factor reduction produce small but real improvements and treat the shared underlying disease. Over-the-counter 'male enhancement' supplements are a notable hazard: sexual-enhancement products are the largest category of FDA-flagged adulterated supplements, and many contain undeclared PDE5-inhibitor drugs — a specific danger for men taking nitrates — while marketed 'testosterone boosters' are largely unsupported. This page addresses erectile dysfunction specifically; low sexual desire is a distinct problem with a different work-up, and is not routed here.
References & sources
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54-61 (PMID 8254833)
- Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011;58(13):1378-1385 (PMID 21920268)
- Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013;6(1):99-109 (DOI 10.1161/CIRCOUTCOMES.112.966903)
- Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 2005;96(12B):19M-23M (PMID 16387561)
- Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44(3):360-364 (PMID 12932937)
- Kouidrat Y, Pizzol D, Cosco T, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med 2017;34(9):1185-1192 (PMID 28722225)
- Cao S, Yin X, Wang Y, et al. Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLoS One 2013;8(4):e60443 (PMID 23573257)
- Farmakis IT, Pyrgidis N, Doundoulakis I, et al. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. Cardiovasc Drugs Ther 2022;36(5):903-914 (PMID 33945044)
- Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63(5):902-912 (PMID 23395275)
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol 2018;200(3):633-641 (PMID 29746858)
- Salonia A, Capogrosso P, Boeri L, et al. EAU guidelines on male sexual and reproductive health: 2025 update. Eur Urol 2025;88(1):76-102 (PMID 40340108)
- Kloner RA, Burnett AL, Miner M, et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J Sex Med 2024;21(2):90-116 (PMID 38148297)
- Zhu J, Zhang W, Ou N, et al. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis. Transl Androl Urol 2020;9(2):591-600 (PMID 32420164)
- Gupta BP, Murad MH, Clifton MM, et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011;171(20):1797-1803 (PMID 21911624)
- Tucker J, Fischer T, Upjohn L, et al. Unapproved pharmaceutical ingredients included in dietary supplements associated with US FDA warnings. JAMA Netw Open 2018;1(6):e183337 (PMID 30646238)
- Clemesha CG, Thaker H, Samplaski MK. 'Testosterone boosting' supplements composition and claims are not supported by the academic literature. World J Mens Health 2020;38(1):115-122 (PMID 31385468)
- US Food and Drug Administration. Tainted sexual enhancement products (Medication Health Fraud). FDA, accessed 2026
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback